Viewpoint
Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?

https://doi.org/10.1016/S0165-6147(00)88999-3Get rights and content

Abstract

Substantial efforts are being made to develop drugs which will protect the brain from the neurodegeneration that follows an acute ischaemic stroke. However, while there are already a significant number of animal models of stroke, there is currently no information as to whether activity of a compound in any of them will predict clinical efficacy. In this article, Jackie Hunter, Richard Green and Alan Cross review the major models of acute cerebral ischaemia and propose rational protocols for examining novel neuroprotective agents.

References (60)

  • R. Bonita

    Lancet

    (1992)
  • L.R. Caplan

    Lancet

    (1992)
  • M.G. Marmot et al.

    Lancet

    (1992)
  • B.K. Siesjö

    Prog. Brain Res.

    (1993)
  • W. Pulsinelli

    Lancet

    (1992)
  • T. Kirino

    Brain Res.

    (1982)
  • A.R. Green et al.

    Neurosci. Lett.

    (1994)
  • M.F. Snape et al.

    Neuroscience

    (1993)
  • C.D. Benham

    Neuropharmacology

    (1993)
  • X. Cao et al.

    Brain Res.

    (1994)
  • M.J. Robinson et al.

    Neurosci. Lett.

    (1990)
  • P.M. Patel et al.

    Surg. Neurol.

    (1991)
  • M. Nedergaard

    Brain Res.

    (1987)
  • C.K. Park et al.

    Neurosci. Lett.

    (1992)
  • R.H. Hatfield et al.

    Eur. J. Pharmacol.

    (1992)
  • R. Gill et al.

    Eur. J. Pharmacol.

    (1990)
  • A.R. Green et al.

    Prog. Neurobiol.

    (1994)
  • J. Bamford

    Lancet

    (1992)
  • D.L. Rogers

    Behav. Brain Res.

    (1992)
  • J. Benavides et al.

    Neurosci. Lett.

    (1990)
  • F.C. Barone

    Brain Res.

    (1993)
  • R.H. Hatfield et al.

    Brain Res.

    (1992)
  • Who Monica Project

    J. Clin. Epidemiol.

    (1988)
  • Stroke

    (1992)
  • N.S. Abramson

    New Engl. J. Med.

    (1986)
  • D.O. Wiebers et al.

    Stroke

    (1990)
  • G.F. Molinari

    Stroke

    (1988)
  • S.E. Karpiak et al.

    Annu. Rev. Pharmacol. Toxicol.

    (1989)
  • C. Millikan

    Stroke

    (1992)
  • I.M. Macrae

    Br. J. Clin. Pharmacol.

    (1992)
  • Cited by (147)

    • Neurobehavioural deficits correlate with the cerebral infarction volume of stroke animals: A comparative study on ischaemia-reperfusion and photothrombosis models

      2012, Environmental Toxicology and Pharmacology
      Citation Excerpt :

      The advantages of MCAO model are the availability of techniques for both permanent and reversible occlusion, the long history of model study and the fact that the majority of human ischaemic strokes result from an occlusion in the region of the MCA. Disadvantages of the model are the large size of the infarcts, the need for extensive surgery, and the marked variability in the damage (Hunter et al., 1995). One of the most attractive and relatively non-invasive models is the photochemically induced stroke model.

    • Hydroxypyridinones as " privileged" chelating structures for the design of medicinal drugs

      2012, Coordination Chemistry Reviews
      Citation Excerpt :

      Since oxidative stress has a recognized main role in the pathogenesis of neurodegenerative diseases, treatments targeting sources of ROS have attracted particular attention [128]. In fact, both anti-oxidants and iron chelating agents have shown neuroprotective efficacy in animal models of AD and PD [129] In particular, the HPs, by chelating the labile iron, can act as antioxidants and thus reduce oxidative stress [130].

    View all citing articles on Scopus
    View full text